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ABSTRACT
The infiltration of melanoma tumors by macrophages is often correlated with 
poor prognosis. However, the molecular signals that regulate the dialogue between 
malignant cells and the inflammatory microenvironment remain poorly understood. 
We previously reported an increased expression of sphingosine kinase-1 (SK1), which 
produces the bioactive lipid sphingosine 1-phosphate (S1P), in melanoma. The present 
study aimed at defining the role of tumor SK1 in the recruitment and differentiation of 
macrophages in melanoma. Herein, we show that downregulation of SK1 in melanoma 
cells causes a reduction in the percentage of CD206highMHCIIlow M2 macrophages in 
favor of an increased proportion of CD206lowMHCIIhigh M1 macrophages into the tumor. 
This macrophage differentiation orchestrates T lymphocyte  recruitment as well as 
tumor rejection through the expression of Th1 cytokines and chemokines. In vitro 
experiments indicated that macrophage migration is triggered by the binding of tumor 
S1P to S1PR1 receptors present on macrophages whereas macrophage differentiation 
is stimulated by SK1-induced secretion of TGF-β1. Finally, RNA-seq analysis of human 
melanoma tumors revealed a positive correlation between SK1 and TGF-β1 expression. 
Altogether, our findings demonstrate that melanoma SK1 plays a key role in the 
recruitment and phenotypic shift of the tumor macrophages that promote melanoma 
growth.
INTRODUCTION
Beside the cancer cells and their surrounding stroma, 
the tumor microenvironment contains innate and adaptive 
immune cells that can recognize and destroy tumor cells. 
However, mounting evidence indicates that tumor cells are 
able to change the functions of infiltrated immune cells to 
generate favorable conditions essential for tumor growth 
and progression [1].
In melanomas, macrophages represent a prominent 
component of the leukocytic infiltrate [2], and a high 
density of melanoma-associated macrophages correlates 
with poor clinical outcome [3]. Monocyte-derived 
macrophages are generally recruited from the blood to the 
tumor site by a wide array of biologically active molecules 
produced by malignant and stromal cells [4]. Infltrating 
macrophages respond to this milieu and can polarize, 
similarly to the CD4+ Th1 versus Th2 cell paradigm, into 
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either M1 (classically activated) or M2 (alternatively 
activated) macrophages according to environmental 
stimuli [5]. Tumor-associated macrophages (TAMs) are 
key orchestrators of cancer-related inflammation and are 
considered to be of the M2 phenotype. These cells produce 
a plethora of growth factors, cytokines, chemokines, 
extracellular matrix proteins, and proteases, which 
promote tumor angiogenesis, growth, metastasis, and 
immune suppression [6, 7]. Indeed, TAMs affect adaptive 
immune responses by recruiting T regulatory cells, which 
in turn suppress antitumor effector cells such as NK cells 
and CD8+ T cells [8, 9].
One of the therapeutic approaches that provides 
clinically important benefit for patients with disseminated 
melanoma whose tumors contain the V600 mutation in the 
BRAF gene is based on the inhibition of the MAP kinase 
pathway with BRAF inhibitors. Interestingly, depletion 
of F4/80 and CD11b positive macrophages enhances the 
antitumor activity of BRAF inhibitors on mouse melanoma 
tumors. Conversely, the presence of macrophages in 
human tumors predicts early relapse after treatment [10], 
suggesting important reciprocal interactions between 
TAMs and malignant cells in melanoma tumors. However, 
the possible underlying mechanisms of these interactions 
are not fully understood and their possible therapeutic 
ramifications await further investigation.
Interestingly, we recently showed an increased 
production of sphingosine 1-phosphate (S1P) in melanoma 
cells [11, 12]. This bioactive sphingolipid metabolite is 
mainly produced by sphingosine kinase SK1, which is 
overexpressed in human melanoma tumors compared 
to nevi [12]. In many tumor models, S1P conveys 
oncogenic signals as an intracellular second messenger 
and/or through a family of G-protein coupled receptors 
(S1PR1-5) expressed both on cancer cells and their 
surrounding microenvironment [13, 14]. In melanoma 
tumors, dysregulation of S1P production in cancer cells 
elicits a fibrotic response in the tumor microenvironment, 
which in turn stimulates melanoma cell migration by 
promoting S1PR3 expression [12]. Additionally, treatment 
of mice with the S1P receptor modulator FTY720, 
which renders cells unresponsive to S1P activation by 
sequestering S1PR1 intracellularly, reduced melanoma 
progression by inhibiting tumor vascularization [15]. 
These findings illustrate the paracrine action of melanoma 
cells-exported S1P through S1PRs on tumor-stroma 
interactions. However, recent studies demonstrate 
that the SK1/S1P/S1PR axis plays an essential role in 
inflammation-associated cancer development [16]. Indeed, 
RNAi-based downregulation of SK1 or S1PR1 has been 
shown to block the persistent activation of the STAT3 
transcription factor and the level of proinflammatory 
cytokines and reduce cancer progression in mouse models 
of inflammation [17, 18].
Therefore, the goal of this study was to investigate 
whether S1P produced by melanoma cells could control 
inflammation in these tumors as well as the antitumor 
immune response. Our present findings provide new 
insights into the role of SK1 in the recruitment and 
differentiation of macrophages and the adaptative immune 
response to control melanoma growth.
RESULTS
Downregulation of SK1 in melanoma cells 
reduces tumor growth and modifies the 
composition of tumor-infiltrating leukocytes
In order to evaluate the effect of SK1 in a syngeneic 
mouse model of melanoma, we first generated stable 
SK1 knockdown clones of B16F10 cells, using shRNA-
mediated silencing technology. As shown in Figure 1A, 
two puromycin-resistant clones (shSK1 and shSK1#3) 
exhibited a markedly reduced mRNA expression as well 
as enzymatic activity of SK1, compared to B16 shCtrl. 
Expression of the SK2 isoenzyme was unchanged in 
SK1-downregulated cells (Supplementary Figure S1A). 
Importantly, B16 melanoma clones exhibited similar 
in vitro cell proliferation rates, irrespectively of SK1 
mRNA level (Supplementary Figure S1B). Then, B16F10 
cells knockdown or not for SK1 were intradermally 
injected in C57BL6 mice, and tumor weight was evaluated 
10 days later. Figure 1B shows that, whereas the in vivo 
tumor growth of shSK1#2 B16F10 was not reduced 
compared to shCtrl B16F10, that of shSK1 and shSK1#3 
B16F10 was significantly lower. The positive correlation 
found between SK1 activity and tumor weight highlights 
the tumor-promoting role of SK1 in melanoma. 
A sphingolipidomic analysis showed that 
downregulation of SK1 in melanoma tumors significantly 
reduced the levels of S1P (Figure 1C, left) but did not alter 
the total ceramide content (Figure 1C, middle). However, 
the levels of C18:0 and C18:1 ceramide were modestly yet 
significantly increased (Figure 1C, right). The alteration 
in S1P content was associated with a decrease in tumor 
volume and growth (Figure 1D).
Then, to study whether and how SK1 could control 
inflammation in melanoma tumors, the leukocyte content 
of tumors, in which SK1 was reduced, was analyzed by 
flow cytometry and compared to that of control tumors. 
On day 10 after B16F10 inoculation, downregulation of 
SK1 did not affect the percentage of CD45+ leukocytes 
among the total cells collected from dissociated tumors but 
led to a 40% decrease in F4/80+ macrophage infiltration 
compared to the control (Figure 2A). Importantly, 
treatment of shSK1 B16 tumor-bearing mice with 
liposome encapsulated clodronate, a macrophage-
depleting agent, abrogated tumor growth reduction 
induced by SK1 knockdown, suggesting that this effect 
is dependent on macrophages (Figure 2B). Moreover, 
the expression of cell surface markers such as the major 
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histocompatibility complex class II (MHC-II) molecules, 
which are highly expressed on M1 macrophages, and 
the mannose receptor CD206, which is a specific marker 
of M2 macrophages, was investigated. As illustrated in 
Figure 2C, downregulation of SK1 in B16 increased the 
percentage of M1-oriented MHC-IIhighCD206low TAMs 
(Figure 2C, left). In accordance, the tumor content of 
inducible nitric oxide synthase (iNOS+) F4/80+ cells 
(Figure 2C, right), which represent M1 macrophages, 
was higher in shSK1 B16 tumors than in shCtrl B16 
Figure 1: SK1 expression in melanoma cells drives tumor development in mice. (A) SK1 mRNA level (left panel) and 
enzymatic activity (right panel) were measured in B16F10 cells stably transfected with a control (shCtrl) or SK1 targeted shRNA (shSK1, 
shSK1#2 or shSK1#3). Data are expressed as fold-change over shCtrl B16F10 cells and are means ± sem of 3–5 independent experiments. 
(B) B16F10 murine melanoma cells (3.105) were injected in the dermis of C57BL/6 mice. After excision 10 days later, tumors were collected 
and weighed (left panel). Data are means ± sem (n = 4 to 5 mice per group). The relationship between SK1 enzymatic activity and tumor 
weight was evaluated with a Pearson correlation analysis (right panel). (C) Cellular lipids were extracted from shCtrl or shSK1 tumors and 
sphingolipid levels were quantified by LC/MS. Levels of S1P (left panel), total ceramide (middle panel) and individual ceramide species 
(right panel) were normalized to protein content. Results represent means ± sem of 2 independent experiments. (D) Tumor volume was 
determined at the indicated days in the mice that were implanted with shCtrl or shSK1 B16F10 cells, as described in B. Results are from 
2 independent experiments performed with 7 mice per group. Values determined for individual tumors are depicted and horizontal lines 
correspond to means. For all panels, significant differences were evaluated using Student t test.
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tumors. In contrast, the percentage of M2-oriented MHC-
IIlowCD206high TAMs was decreased in melanoma tumors 
in which SK1 was inhibited (Figure 2C, middle).
In addition, downregulation of SK1 in B16 led to 
an increased expression of Th1 cytokines (IL-12, TNFa, 
IFNg) and chemokines (CCL5, CXCL9, CXCL10) into 
Figure 2: Expression of SK1 in melanoma cells alters the tumor infiltration and phenotype of macrophages. (A, C) 
shCtrl or shSK1 B16F10 murine melanoma cells were injected in C57BL/6 mice. Ten days after injection, mice were sacrificed, tumors 
were collected, and their leukocyte content was analyzed. Bars represent means ± sem of 4 mice per group. Data are representative of 
two independent experiments. Significant differences were evaluated using Student t test. (A) Cells were counted and the percentage of 
CD45 and F4/80 among total cells was determined by flow cytometry. (B) Mice (n = 5–6/group) bearing shCtrl or shSK1 B16 tumors were 
treated with control liposomes (L-Control) or clodronate-containing liposomes (L-Clodronate) the day before tumor cell injection and 
then every 4 days for 2 weeks. Tumor volume was determined 13 days after melanoma cell implantation. Values determined for individual 
tumors are depicted and horizontal lines correspond to means. Data are representative of two independent experiments. Statistical analysis 
was performed using the Mann-Whitney U-test. (C) Representative flow cytometry density plots. Values indicate the percentages of 
MHC-IIhigh CD206low (left panel), MHC-IIlow CD206high (middle panel) and iNOS+ (right panel) cells among the F4/80+ cells. (D) Ten days 
after injection, tumors were collected for mRNA isolation and analysis. Relative mRNA expression (fold induction relative to shCtrl) is 
depicted for M2 markers (YM1 and ARG-1) and M1 markers (Il12, Tnfα, Ifnγ, Ccl5, Cxcl9, Cxcl10). Significant differences were evaluated 
using Student t test. NS: not significant. 
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the tumor. In accordance, whereas mRNA expression 
of iNOS was significantly higher in shSK1 B16 tumors 
compared to that of shCtrl B16 tumors, the expression 
of the M2 markers YM1 and arginase-1 (ARG-1) was 
unchanged (Figure 2D).
Because M1 macrophages process tumor antigens 
and present them to T lymphocytes, which become 
activated, proliferate, and infiltrate the tumor [19], 
we next investigated the percentage of T lymphocytes 
in melanoma tumors. Interestingly, the proportion of 
different lymphocyte subpopulations was altered in tumors 
in which SK1 was inhibited, with a significant increase 
of NK cells as well as T-cells (Thy1+) such as CD4+ and 
CD8+ tumor-infiltrating lymphocytes (Supplementary 
Figure S2). In contrast, the percentage of B lymphocytes 
was decreased in tumors in which SK1 was reduced. 
In addition, the proportion of intratumor CD11b+Gr1+ 
myeloid suppressor-type cells was not modified by SK1 
downregulation.
Collectively, our data indicate that melanoma 
SK1/S1P can control tumor growth by regulating the 
migration and polarization of macrophages.
Downregulation of SK1 in melanoma cells 
impairs the migration of bone marrow-derived 
macrophages via S1PRs
To explore the chemotactic behavior of macrophages 
in response to the melanoma SK/S1P/S1PR signaling 
pathway, bone marrow-derived macrophages (BMDM) 
were incubated with the conditioned medium (CM) 
from shCtrl or shSK1 B16 cells, and analyzed for their 
ability to migrate toward factors secreted by melanoma 
cells. Results show that depletion of SK1 in B16 cells 
led to reduced release of S1P in the medium (Figure 3A). 
Moreover, whereas the CM from shCtrl B16 cells exerted 
a powerful pro-migratory effect on BMDM as compared 
to BMDM incubated in medium alone, this effect was 
strongly attenuated when BMDM were exposed to the 
CM from shSK1 B16 cells (Figure 3B, left). Importantly, 
BMDM migration was restored by adding exogenous 
S1P to the CM of shSK1 B16 cells. Since S1PR1, 
2 and 3 are expressed by BMDM [20], we next examined 
whether S1PR1 and S1PR3, which are known to promote 
cell migration, are implicated in BMDM migration upon 
incubation with melanoma CM. Figure 3B (right) shows 
that pretreatment of BMDM with the S1PR1 antagonist 
W146 or the S1PR1/3 antagonist VPC23019 impaired 
the migratory effect exerted by the CM from shCtrl B16 
cells. Moreover, the direct treatment of BMDM with 
exogenous S1P mimicked, in a dose-dependent manner, 
the macrophage migration induced by the CM from shCtrl 
B16 cells. Again, pretreatment with VPC23019 abrogated 
S1P-induced BMDM migration (Figure 3C).
To confirm that melanoma SK1 controls 
macrophage migration, we used the human melanoma cell 
line COLO829, which is devoid of SK1 protein [12], and 
generated the COLO829(SK1) variant, which exhibited a 
sharp increase in mRNA expression (Figure 3D, left) as 
well as enzymatic activity (Figure 3D, middle) of SK1. 
These modifications led to increased S1P release in the 
CM from melanoma cells (Figure 3D, right). Then, we 
analyzed the migration of the human monocytic cell 
line THP-1 upon incubation with the CM either from 
COLO829(SK1) or control COLO829. The results show 
that THP-1 cell migration was enhanced upon incubation 
with the medium from COLO829 cells, a phenomenon 
further augmented when melanoma cells overexpressed 
SK1 (Figure 3E). Pretreatment of THP-1 cells with 
VPC23019, W146 or the S1PR1 modulator FTY720 
abrogated the migratory effect exerted by the CM from 
COLO829 cells (Figure 3E). A significant reduction 
in macrophage migration was also obtained when 
THP-1 cells were transiently transfected with siRNA 
against S1PR1 (Figure 3F). Moreover, S1P treatment of 
THP-1 cells mimicked the macrophage migration induced 
by the CM from melanoma cells. Again, inhibitors 
targeting S1PR1 abrogated S1P-induced macrophage 
migration (Figure 3G).
Altogether, these results suggest that S1P produced 
by melanoma cells stimulates macrophage migration in a 
S1PR1-dependent manner.
Downregulation of SK1 in melanoma cells 
induces the expression of M1 markers in bone 
marrow-derived macrophages
Because an increased number of M1-oriented 
MHC-IIhighCD206− TAMs were present in shSK1 melanoma 
tumors (see Figure 2C), we next studied the effect of SK1 
inhibition on macrophage polarization in vitro. To this end, 
BMDM were incubated with the CM of B16 melanoma cells 
and the expression of M1 and M2 markers was analyzed. 
As shown in Figure 4, whereas downregulation of SK1 in 
shSK1 B16 cells significantly increased the expression of 
iNOS in BMDM, it also led to a strong decrease of ARG-1 
expression. Moreover, the expression of Th1 cytokines and 
chemokines was increased in BMDM upon incubation with 
CM from shSK1 B16 cells as compared to those treated with 
CM from shCtrl B16 cells. Similar results were obtained 
when B16 cells were exposed to SKI-I, a pharmacological 
inhibitor of SK1 (data not shown). Interestingly, for most 
M1 markers, a further increase in the mRNA expression 
was observed (Figure 4A) when shSK1 B16 cells were 
pre-treated with SKI-I, which led to further inhibition of 
SK1 enzymatic activity (Figure 5B, left). These results 
demonstrate an inverse correlation between melanoma 
SK1 enzymatic activity and the expression of M1 markers 
in BMDM. Conversely, a positive corelation was found 
between SK1 activity and the expression of the M2 markers, 
CD206 and ARG-1 (Figure 4A) but not for YM1 (data not 
shown).
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To determine whether these effects could be 
related to S1P secretion from melanoma cells, BMDM 
were preincubated or not with VPC23019 before the 
addition of the CM from shCtrl B16 cells. Figure 4B 
shows that the expression of M1 and M2 markers was not 
significantly modified by S1PR antagonism. Accordingly, 
direct treatment of BMDM with 1 µM (Figure 4C) or 
5 µM (data not shown) S1P did not induce any variations 
Figure 3: Macrophage migration is increased by melanoma-derived S1P. (A) S1P release from shCtrl or shSK1 B16F10 
melanoma cells as determined after the conversion of [3H]sphingosine to [3H]S1P. Concentrations of radiolabeled S1P in the medium are 
expressed as mean ± sem of three independent experiments. Significant differences were evaluated using Student t test. Transwell migration 
assays were performed to evaluate migration of BMDM (B and C) or THP-1 cells (E–G). Data are expressed as percent increase or 
decrease over migration in serum-free medium, and are means ± sem of 2–4 independent experiments. For panels B, C and E-G, significant 
differences were evaluated using one-way ANOVA with post hoc Tukey test. (B and C) BMDM were pre-treated (+) or not (−) with 
2 µM VPC23019 (VPC) or 5 µM W146 for 1 hour. Then, BMDM were incubated for 5 hours in serum-free medium alone (Medium), the 
conditioned medium (CM) from shCtrl or shSK1 B16F10 melanoma cells containing or not S1P (B) or in serum-free medium containing 
S1P at the indicated concentrations (C). (D) SK1 mRNA expression (left panel), enzymatic activity (middle panel) and S1P release (right 
panel) were measured in COLO829 melanoma cells transfected either with an empty vector (Vector) or a plasmid encoding human SK1 
(SK1). Data are means ± sem of 3 independent experiments. Significant differences were evaluated using Student t test. E and G, THP-1 
cells were pre-treated or not with 2 µM VPC23019, 2 µM FTY720 (FTY) or 5 µM W146 for 1 hour. Then, THP-1 cells were incubated for 
6 hours in the CM from control (Vector) or SK1-overexpressing (SK1) COLO829 melanoma cells (E) or in serum-free medium containing 
S1P at the indicated concentrations (G). F, Melanoma CM-induced cell migration was evaluated, as described in E, on THP-1 cells 48 hours 
after transfection with control (Ctrl) or S1PR1 siRNA (20 nM). Silencing of S1PR1 in THP-1 cells by siRNA was assessed by Western blot.
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in macrophage differentiation as compared to BMDM 
incubated in medium without S1P.
Altogether, these findings indicate that macrophage 
polarization induced by melanoma SK1 occurs through a 
S1P/S1PR-independent way.
SK1-induced secretion of TGF-β1 stimulates 
macrophage polarization
To study further on the molecular mechanisms 
that control macrophage polarization, we analyzed an 
RNA-seq dataset obtained from a collection of 472 
human cutaneous melanoma tissue samples (TCGA). We 
observed that the expression of the immunosuppressive 
cytokine TGF-β1 was slightly, albeit significantly, 
lower in samples displaying a lower SK1 expression 
(Figure 5A ; p < 0.0001), supporting a positive correlation 
between SK1 and TGF-β1 expression in human melanoma 
tumors. Moreover, given that SK1 expression has 
been reported to correlate with the levels of TGF-β1 
in different inflammation-based experimental models 
[21, 22], we next explored whether the effects of 
Figure 4: Macrophage polarization is controlled by melanoma SK1 through a S1PR-independent mechanism. BMDM 
were incubated for 24 hours in the conditioned medium (CM) from B16F10 melanoma cells (A and B) or serum-free medium containing or 
not 1 µM S1P (C). Relative mRNA expression is depicted for M2 markers (Mrc1 (CD206), Chi3l3 (YM1) and Arg1) and M1 markers (iNos, 
Il12, Tnfα, Ifnγ, Ccl5, Cxcl9, Cxcl10). Data are plotted against the SK1 activity of B16F10 melanoma cells submitted to distinct treatments. 
(A) CM was prepared from shCtrl or shSK1 B16F10 melanoma cells treated or not with 3 µM SKI-I for 48 hours. (B) BMDM were pre-
treated with 2 µM VPC23019 before incubation with the CM from shCtrl B16F10 melanoma cells. Data are expressed as fold-increase 
over shCtrl B16F10 cells and are means ± sem of 2–6 independent experiments. (C) Data are expressed as fold-change over migration in 
serum-free medium, and are means ± sem of 3–4 independent experiments. For all panels, significant differences were evaluated using 
Student t test.
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melanoma SK1 on macrophage polarization could be 
mediated by TGF-β1. Quantification of relative mRNA 
expression (Figure 5B, middle) as well as ELISA 
performed on cell-free supernatants (Figure 5B, right), 
revealed that downregulation of SK1 (Figure 5B, left) is 
associated with a significant decrease in TGF-β1 levels 
in melanoma cells, this phenomenom being amplified by 
SKI-I.
As most of the SK1/S1P-dependent immuno-
modulatory effects are attributed to S1PR ligation, we 
next investigated the role of S1PRs in the regulation of 
SK1-induced TGF-β1 gene expression. Figure 5C shows 
that inhibition of S1PRs with three different antagonists, 
including the S1PR2-specific antagonist JTE013, or the 
direct treatment of B16F10 with exogenous S1P did not 
significantly change the TGF-β1 transcript levels. These 
results suggest that SK1-induced TGF-β1 gene expression 
is independent of the S1P/S1PR signaling pathways in 
melanoma cells.
Interestingly, addition of a recombinant TGF-β1 
protein to the CM of shSK1 B16F10 rescued the ability 
of BMDM to polarize toward an M2 phenotype in 
response to melanoma cell signals. Moreover, under these 
conditions, the expression of M1 markers was reduced 
(Figure 5D). Reciprocally, addition of an anti-TGF-β 
neutralizing antibody to the CM shCtrl B16F10 increased 
the expression of M1 markers in BMDM (Figure 5E). 
This effect mimicked the response observed in BMDM 
incubated with the CM from shSK1 B16F10 (Figure 4A). 
Finally, treatment of shCtrlB16 tumor-bearing mice with 
an anti-TGF-β resulted in a tendency to tumor regression 
(Figure 5F). These findings indicate that melanoma SK1 
stimulates macrophage differentiation as well as tumor 
growth through TGF-β1 production.
DISCUSSION
Inflammation has long been associated with 
the development of cancer. A common feature of 
melanoma is the infiltration of immature macrophages 
at early stages of tumorigenesis. These cells modulate 
the activity of T lymphocytes and stroma cells, either 
promoting or inhibiting tumor progression depending on 
TAM infiltration density and differentiation status [23]. 
Accordingly, it has been shown in different murine tumor 
models that either depletion of macrophages or switching 
the phenotype of these cells into tumor-fighting M1 
macrophages can significantly halt tumor growth [24, 25].
Here, we report for the first time that SK1 regulates 
melanoma growth by modulating the macrophage 
infiltration of the tumor (see Figure 6). Indeed, the 
percentage of F4/80+ macrophages was lower in tumors 
in which SK1 was silenced than in control tumors. In 
accordance, a large increase of SK1 protein is associated 
with an increased infiltration of macrophages into tumor 
tissues of Sphk2−/− mice developing colitis-associated 
cancer. In the latter model, SK1 and S1PR1 stimulate 
tumor growth and drive TAMs and dendritic cells to 
produce elevated IL-6 levels, thereby promoting a pro-
inflammatory tumor microenvironment [18]. These 
observations suggest that SK1 could be involved in the 
migration/trafficking of macrophages leading to their 
infiltration of tumors. In vitro, our findings demonstrate 
that S1P produced by melanoma SK1 acts as a potent 
chemoattractant for macrophages in a S1PR1-dependent 
manner. Indeed, treatment of murine BMDM or the 
human cell line THP-1 with exogenous S1P promoted 
cell migration. Our results were obtained on THP-1 cells 
differentiated into macrophage-like cells by PMA, as 
under these conditions THP-1 cells recapitulate several 
features of human native monocyte-derived macrophages. 
THP-1 cells are widely used to investigate migration 
and differentiation of human macrophages in response 
to various inflammatory mediators. Here, we show 
that after treatment with S1P, THP-1 cells migrate as 
previously reported for human native monocyte-derived 
macrophages [26]. Whether S1P produced by melanoma 
SK1 stimulates macrophage infiltration through activation 
of S1PR in vivo remains to be determined. Nevertheless, 
in different experimental mouse models of inflammation, 
FTY720 reduced macrophage recruitment to the sites of 
inflammation, demonstrating that S1PR1 can be critical 
for macrophage trafficking in vivo [27, 28]. In contrast, 
downregulation in cancer cells of the SK2 isoform, which 
differs from SK1 by its subcellular localization, failed to 
reduce the number of macrophages in breast tumors [29].
Our study also identified SK1 as a key regulator 
of macrophage polarization in melanoma tumors (see 
Figure 6). Indeed, whereas knockdown of SK1 
significantly increased the percentage of MHC-
IIhighCD206low M1 macrophages into the tumor, it reduced 
the proportion of MHC-IIlowCD206high M2 macrophages. 
Moreover, the ratio of iNOS to ARG-1 gene expression, 
which is commonly used as a readout of macrophage 
functional status, was also increased in shSK1 B16 
tumors. M1 macrophages are potent tumor-fighting cells 
and are able to suppress M2-associated tumor-promoting 
functions by a poorly understood mechanism [30]. 
Through the expression and secretion of cytokines and 
chemokines such as IL-12, CXCL9 and CXCL10, M1 
macrophages drive the polarization and recruitment of 
Th1 cells. Reciprocally, by producing IFNγ, Th1 cells can 
drive classical M1 polarization of macrophages, thereby 
amplifying a type 1 response [31]. Our in vitro findings 
demonstrate that melanoma SK1 enzymatic activity 
correlates with a decrease of M1 markers, and conversely, 
an increase of M2 markers in BMDM. Previous reports 
have suggested that stimulation of S1PR1 by S1P reduces 
the expression of iNOS, TNFa, MCP-1 and IL-12, and 
induces ARG-1 expression in LPS-treated macrophages 
[32]. S1P-induced M2 polarization also occurs through 
IL-4 secretion in LPS-treated mouse peritoneal 
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macrophages [33]. Here, we show that the phenotypic 
switch of macrophages induced by melanoma SK1 does 
not rely on the binding of S1P to S1PRs on macrophages. 
Indeed, the expression of M1- and M2-specific markers 
was not modified in macrophages pretreated with 
VPC23019 as compared to that of macrophages incubated 
with CM alone. Furthermore, addition of exogenous S1P 
to BMDM failed to promote macrophage polarization.
Figure 5: Melanoma SK1-induced TGF-β1 stimulates macrophage polarization. (A) Analysis of SK1 and TGF-β1 expression 
in melanoma tumors was carried out using the TCGA database. (B) SK1 enzymatic activity (left), TGF- β1 mRNA expression (middle) 
and TGF- β1 secreted protein level (right) were measured in shCtrl or shSK1 B16F10 melanoma cells treated or not with 3 µM SKI-I for 
48 hours. (C) TGF- β1 mRNA level was measured in shCtrl B16F10 melanoma cells pretreated or not with 2 µM VPC23019, 2 µM FTY720 
or 10 µM JTE013 and incubated with 1 µM S1P for 24 hours. Data are expressed as fold-increase over shCtrl B16F10 cells and are means 
± sem of 2–3 independent experiments. Significant differences were evaluated using Student t test. (D and E) BMDM were incubated for 
48 hours in the conditioned medium (CM) from shCtrl or shSK1 B16F10 melanoma cells. Relative mRNA level is depicted for M2 markers 
(CD206, YM1 and Arg-1) and M1 markers (iNos, Il12, Tnfα, Ifnγ, Ccl5, Cxcl9, Cxcl10). D, Recombinant murine TGF-β1 (50 ng/ml) was 
added to the CM from shSK1 B16F10 melanoma cells before incubation with BMDM. E, Anti-TGF-β1 (1 µg/ml) was added to the CM 
from shCtrl B16F10 melanoma cells before incubation with BMDM. Results represent means ± sem of 2–3 independent experiments. 
Significant differences were evaluated using Student t test. (F) Mice (n = 6/group) bearing shCtrl B16 tumors were treated with TGF-b-
neutralizing antibody or PBS, one day after tumor cell injection and then three times per week for 2 weeks. Tumor volume was determined 
13 days after implantation. Values determined for individual tumors are depicted and horizontal lines correspond to means. Data are 
representative of two independent experiments. Statistical analysis was performed using the Mann-Whitney U-test
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Our observations clearly show that melanoma SK1 
stimulates tumor-derived TGF-β1 secretion, which leads 
to the differentiation of macrophages poorly expressing 
M1 phenotype genes. Neutralization of TGF-β1 in the CM 
from control melanoma cells stimulated M1 markers in 
BMDM. TGF-β1 signaling has previously been reported 
to be activated following ligation of S1PR2 by S1P [34]. 
Here, we demonstrate that SK1-induced TGF-β1 mRNA 
expression is not mediated by an autocrine S1P signaling 
loop through S1PRs. However, given that SK1 has been 
shown to activate transcription factors such as HIF-1α 
[35] or NF-κB [36] in various tumors and that TGF-β1 
expression is induced by these factors [37, 38], one can 
speculate that SK1 stimulates TGF-β1 expression at 
a transcriptional level. However, this hypothesis still 
requires further investigation. Melanoma produces 
increasing amounts of TGF-β1 with disease progression 
[39]. TGF-β1 is one of the most potent immunosuppressive 
cytokine secreted by tumor cells. Notably, TGF-β1 
counteracts effector functions of macrophages, NK cells, 
cytotoxic T lymphocytes and dendritic cells as well as 
cytokine secretion [40]. On macrophages, binding of 
TGF-β1 to its receptor leads to activation and nuclear 
translocation of Smad molecules, which cooperate with 
other transcription factors to regulate gene expression and 
reprogramme macrophages to the M2 phenotype [41].
Finally, in a number of preclinical models, several 
TGF-β inhibitors, including small-molecule inhibitors 
targeting type I and II TGF-β receptor activity, monoclonal 
antibodies neutralizing TGF-β ligands and antisense 
oligonucleotides blocking TGF-β ligand production have 
demonstrated antitumor activity. For instance, in B16 
murine melanoma, anti-TGF-β therapy in combination 
with interleukin-2 reduced the number of lung metastases 
[42]. In melanoma patients, the baseline serum TGF-β 
levels were significantly higher than those in the control 
group [43]. Recently, an antitumor activity has been 
described for fresolimumab, a human anti-TGF-β 
monoclonal neutralizing antibody, which was administered 
to patients with advanced malignant melanoma [44]. 
Collectively, our data identify a novel role for 
the S1P-producing enzyme SK1 as a key regulator of 
the balance between inflammatory and suppressive 
macrophages in melanoma tumors.
MATERIALS AND METHODS
Cell culture and generation of conditioned 
medium
Melanoma cell lines were obtained from ATCC 
and grown as monolayers in RPMI or DMEM media 
supplemented with 10% heat-inactivated fetal calf 
serum (FCS) in the presence of 5% CO
2
 in a humidified 
atmosphere at 37°C. To guarantee cell line authenticity, 
B16F10 and COLO829 cell lines were used for a limited 
number of passages and routinely tested for the expression 
of melanocyte-lineage proteins such as MelanA/MART1. 
Human monocytic THP-1 cells obtained from Dr. A. Coste 
(University of Toulouse, France) were cultured in RPMI 
Figure 6: Role of melanoma SK1/S1P on macrophage migration and polarization Expression of TGF-β1 in melanoma 
cells is activated by the SK1/S1P pathway. Co-incubation of macrophages with melanoma cells leads to increased ARG-1 expression 
and, inversely, decreased iNOS expression. This is associated with increased expression of M2-related cytokines and, inversely, decreased 
expression of M1-related cytokines as well as TCD8+ response, leading to increased tumor growth. Whereas blocking TGF-β1 with an anti-
TGF-β neutralizing antibody abolished macrophage polarization towards an M2 phenotype, antagonism of S1PR1 inhibited macrophage 
migration induced by S1P.
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containing 10% FCS and 0.02 mM β-mercaptoethanol. 
THP-1 cells were differentiated into macrophages by 
stimulation with 20 ng/ml PMA (Sigma) for 24 hours; then 
cells were cultured for an additional 24 hours without PMA.
Conditioned media (CM) were produced by 
culturing melanoma cells in serum-free RPMI for 
48 hours. In some experiments, melanoma cells were 
treated with 3 µM sphingosine kinase inhibitor SKI-I 
(5-(2-Naphthalenyl)-1H-pyrazole-3-carboxylic acid 
2-[(2-hydroxy-1-naphthalenyl)methylene]hydrazide; 
Abcam). At the end of the culture period, the CM were 
collected, centrifuged for 5 min at 1500 rpm and filtered. 
Macrophages were then treated with the CM alone or in 
the presence of 5 µM S1P, 50 ng/ml recombinant TGF-β1 
(Ebioscience SAS, Paris, France) or 1 µg/ml TGF-β1 
antibody (Clone #1D11, R&D systems, Lille, France) for 
48 hours.
Isolation and culture of BMDM
Bone marrow cells were isolated from femurs 
and tibias of 12-week-old C57BL/6 mice and cultured 
(1.3 × 107/dish; Bioscience Inc) in RPMI containing 
10% FCS and 20 ng/ml recombinant murine macrophage 
colony-stimulating factor (rmM-CSF; Immunotools). 
After 7 days, adherent BMDM were harvested, counted 
and incubated or not with CM from melanoma cells.
Cell transfection
B16F10 cells were co-transfected, in a 1:10 ratio, 
with the pEGFP-C1 empty vector plus one SK1 shRNA 
plasmid (shSK1 B16F10, 3 different shRNA from 
Thermoscientific were used) or a control (shCtrl B16F10) 
non-targeting shRNA plasmid (pLK01, Addgene). The 
hairpin sequences were:
5ʹ-CCGG-GCACCCAAACTACCTTTGGAT-
CTCGAG-ATCCAAAGGTAGTTTGGGTGC-TTTTT-3ʹ 
for shSK1, 5ʹ-CCGG-GAGGCAGAGATAACCTTTAAA-
CTCGAG-TTTAAAGGTTATCTCTGCCTC-TTTTT-3ʹ for 
shSK1#2 and 5ʹ-CCGG-GCAGGTGACTAATGAAGACCT-
CTCGAG-AGGTCTTCATTAGTCACCTGC-TTTTT-3ʹ for 
shSK1#3.
In brief, 500 000 cells were seeded in T25 
cell culture flasks. The plasmids were diluted in 
OptiMEM (Thermofisher) medium without serum. 
Cells were transfected with 5 µg shRNA oligomer using 
Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instructions. Transfected cells were 
selected with 0.75 mg/ml G418 and 2 µg/ml puromycin 
and GFP-expressing cells were sorted by FACS. Stable 
transfectants were maintained in media containing 
1 µg/ml puromycin; for the experiments, cells were 
cultured in medium without puromycin.
COLO829 were transfected with pcDNA3.1 
or pcDNA3.1-SK1 plasmid (kindly obtained from 
Dr. SM. Pitson, Centre for Cancer Biology, Australia) and 
stable transfectants were selected for their resistance to 
0.75 mg/ml G418 (Sigma).
Transient RNA interference was achieved by using a 
pool of four small interfering RNAs (siRNA) specific for 
S1PR1 (ON-TARGETplus SMARTpool; Dharmacon) or 
scrambled siRNA. Cells were transfected using HiPerfect 
Reagent (Qiagen) and inhibition efficiency was evaluated 
48 h after transfection by Western blot. Monoclonal 
anti-EDG1 (S1PR1) and polyclonal anti-b-actin were 
purchased from Abcam and Cell Signaling, respectively.
In vitro motility assay
Transmembrane cell migration assays were 
performed using Boyden chambers containing membranes 
with a pore size of 8 µm (Corning). One million cells 
of BMDM  or THP-1 cells were suspended in serum-
free DMEM in the presence or not of 2 µM VPC23019 
(Coger, Paris, France), 5 µM W146 (Sigma) or 2 µM 
FTY720 (Sigma), and then added on top of the inserts. 
The bottom chamber was filled with CM from melanoma 
cells containing or not S1P (Biovalley, Nanterre, France) 
or serum-free medium either alone or containing S1P at 
the indicated concentrations. After the indicated time, 
macrophages that migrated to the underside of the insert 
membranes were harvested and quantified using a Coulter 
cell counter (Beckman).
Quantitative RT-PCR
RNA from cells or tumors was extracted (RNeasy 
kit, Qiagen) according to the manufacturer’s protocol and 
treated with RNase-free DNase (Qiagen). RNA quality 
was assessed by automated gel electrophoresis (Experion, 
BioRad). One µg of RNA was reverse transcribed 
(SuperScript II, Invitrogen) and the cDNA used as a 
template for qPCR. The reactions were performed in 
duplicate on the StepOne instrument (Applied Biosystems) 
using SYBR Green PCR kit and primer assay (QuantiTect, 
Qiagen). Results were quantified using the StepOne 
system software. mRNA of 18S and b-actin were analyzed 
for normalization. All the primers used were listed in 
Supplementary Table S1.
Analysis of lipids
Lipids were extracted from tumors 10 days after 
melanoma cell implantation, and sphingolipids were 
quantified by ultra-performance liquid chromatography, 
using an Agilent 1290 system coupled to a G6460 triple 
quadripole spectrometer (Agilent Technologies) [45]. 
Alternatively, the amount of extracellular S1P was 
evaluated as reported [46] after incubation of the cells 
with 0.45 µCi/ml, 1.5 µM D-erythro-[3-3H] sphingosine 
(Perkin-Elmer).
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SK1 enzymatic assay 
SK1 activity was determined as described [47] with 
minor modifications.
ELISA for mouse TGF-β1
Murine TGFβ-1 from cell-free B16-F10 supernatants 
was measured by ELISA kit (Abcam) following the 
manufacturer’s instructions.
Bioinformatics
SK1 and TGF-β1 mRNA expression levels were 
assessed in melanoma patients of the Cancer Genome 
Atlas (TCGA) Skin Cutaneous Melanoma (SKCM) 
cohort (n = 472). Level 3 data was interpreted using 
gene transcription estimates as in RSEM normalized and 
centered log2 counts (https://genome-cancer.ucsc.edu/). 
Expression levels were correlated using Pearson product-
moment correlation.
Orthotopic melanoma grafts in mice
Animal experiments were conducted in accordance 
with national and international policies, and our protocol 
was approved by the Regional Ethics Committee of 
Midi-Pyrénées. shCtrl or shSK1 B16F10 cells (3.105) 
were intradermally injected into the flank of 8-week-old 
C57BL/6 mice (Charles River, L’Arbresle, France). In 
some experiments, TGF-b-neutralizing antibody (1D11, 
Bio X Cell, 10 mg/kg) or PBS were i.p. administered three 
times per week starting one day after tumor cell injection 
and during 2 weeks.
To assess the contribution of macrophages to tumor 
growth, macrophages were depleted by i.p. administration 
of 200 µl of Liposomal Clodronate (Encapsula 
NanoSciences LLC) the day before tumor cell injection 
and then every 4 days for 2 weeks, as reported [48].
Tumor volume was calculated using a caliper at the 
indicated days as described [12]. Alternatively, tumors 
were removed at the indicated time after injection and 
weighed.
Analysis of leukocyte content in tumors
B16F10 cells (3.105) were intradermally injected 
into C57BL/6 mice. At day 10, mice were sacrificed and 
tumors were collected. Cells were counted and stained 
with the indicated antibodies and live-dead reactive 
dyes (Invitrogen) prior to flow cytometry analysis (BD 
LSRFortessa) [49]. Analyses were restricted to viable 
cells and performed using anti-CD45 (BD Biosciences, 
BUV395), anti-F4/80 (eBioscience, APC), anti-MHC-II 
(eBioscience, APC-e780), anti-CD206 (Biolegend, FITC) 
or anti-iNOS (Biolegend, PE-Cy7) antibody. Isotype 
controls were from Biolegend or eBioscience.
Statistical analyses
Results are expressed as means ± sem, and group 
comparisons were performed with an unpaired two-
tailed Student’s t test for comparison of 2 groups, or one-
way ANOVA followed by the post hoc Tukey test for 
comparison of experiments that consisted of ≥ 3 groups. 
The Mann-Whitney U-test was used to test statistical 
significance of differences in mean tumor growth between 
independent groups after treatment. Spearman’s rank 
correlation test was used to determine the correlations of 
tumor size (Prism 6; GraphPad Software Inc, San Diego, 
CA). Pearson correlation was performed using GraphPad 
Prism. A p-value less than 0.05 was considered statistically 
significant (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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